Perimenopause: which hormone levels change first
The key points at a glance
Perimenopause refers to several years before and one year after the final menstrual period, with the duration varying considerably (MSD Manual, professional edition, as of January 2024). The menopausal transition within it typically lasts four to eight years until the final menstrual period.
The sequence of changes has been described. First, the cycle becomes irregular, then FSH and LH rise, and the estrogen level eventually drops significantly. For the late menopausal transition, the same source gives an FSH level above 25 IU/L on cycle days 2 to 5.
You will first learn what perimenopause actually is. Then come the figures for the timeline, a comparison of the stages, the role of FSH, why a single measurement is rarely enough, who may benefit from testing, and the limitations of a snapshot.
What to expect in this article
1. What perimenopause is
2. The sequence in which hormone levels change
3. The first sign is not found in the blood
4. The timeline in numbers
5. Why FSH is the value that stands out first
6. Comparing the stages
7. Why a single measurement is rarely enough
8. What other explanations need to be considered
9. Who may benefit from testing
10. What a capillary blood test can show here
11. Limitations: what a snapshot cannot show
12. What matters during perimenopause
Frequently asked questions
Sources
What perimenopause is
Menopause itself is a point in time, not a phase. It is the final menstrual period, and it can only be determined retrospectively, once a year has passed afterward.
Perimenopause is the surrounding phase. The professional edition of the MSD Manual defines it as several years before and one year after the final menstrual period, with the duration varying considerably (as of January 2024).
The menopausal transition falls within this phase. The same source describes it as typically lasting four to eight years until the final menstrual period. This is when the changes discussed here take place.
Why the terms get mixed up in everyday language
In everyday language, the word menopause refers to everything as a whole. In professional literature, the terms refer to different things, and this distinction matters when reading a test result.
Menopause is a point in time, perimenopause is a phase, and the menopausal transition is the part of that phase that occurs before that point. Postmenopause follows.
In practical terms, this means that anyone who wants to know where they stand is not looking for a boundary but for a phase. And phases are difficult to pin down to a single number.
That is precisely why this article focuses on the sequence of the levels rather than on a threshold. A threshold would create an illusion of precision that the process does not support.
The sequence in which the levels change
The underlying mechanism has been described, and it explains why FSH is the one that becomes abnormal early.
Documented source
“Decreased concentrations of inhibin and estrogens from the ovary, which inhibit the release of LH and FSH, lead to a substantial increase in LH and FSH levels.”
JoAnn V. Pinkerton, MD
MSD Manual, professional edition, Menopause, as of January 2024
The sentence describes a feedback loop that is becoming unbalanced. Inhibin and estrogens from the ovaries normally inhibit the release of LH and FSH from the pituitary gland.
When the brake weakens, the two regulatory hormones rise. They rise because the body adjusts its regulation, not because something is broken.
Why the regulatory hormone responds before the target hormone
The mechanism determines the sequence. First, feedback from the ovaries weakens; then the regulatory hormone rises; only later does the estrogen level become significantly lower.
The same source puts it this way: During the transition, estrogen levels eventually decrease significantly, while changes in other hormones vary (as of January 2024).
In practice, this means that an FSH level may already be abnormal while an estradiol level still appears normal. This is not a contradiction but the temporal sequence of the process.
The first sign is not found in the blood
Before any lab value comes an observation that can be made without testing. The MSD Manual describes a variable cycle length during the early transition phase and defines it precisely.
The source cites a persistent difference of at least seven days in the lengths of consecutive cycles (as of January 2024). For the late phase of the transition, it specifies amenorrhea lasting at least 60 days.
This is practical information. Anyone who records their cycle lengths has a criterion that no blood test can replace—and that no blood test makes unnecessary.
A six-month cycle calendar is therefore the most useful first step. It costs nothing and provides exactly the information a single lab value lacks: a pattern over time.
The timeline in numbers
Three figures from the same source help put the timeline into perspective. All three are given in years.
Documented figures for the timeline
4–8
years: typical duration of the menopausal transition until the final menstrual period (MSD Manual, professional edition, as of January 2024)
51
years: average age of physiological menopause in the United States (as of January 2024)
7,4
Years: average duration of vasomotor symptoms, meaning hot flashes and episodes of sweating (as of January 2024)
The third figure surprises most people. Vasomotor symptoms last an average of 7.4 years, which is considerably longer than the widespread idea of a brief transition phase would suggest.
All three figures are averages. For an individual, they say nothing about her own course, and the source explicitly emphasizes that the duration varies considerably.
What an average can still provide here
An average does not answer the question of how the individual course will unfold. It answers a different question, one that is asked more often in everyday life: whether what is happening right now fits within a known range.
Someone who has had irregular cycles for two years and thinks this should have been over by now can find context in the figure of four to eight years. It does not change the situation, but it makes it less unexpected.
The same applies to the 7.4 years. This figure contradicts the widespread image of a short phase, and someone who knows it plans differently from someone expecting it to end soon.
None of the three figures provides a prediction. The average age of 51 says nothing about an individual woman who is 47 or 55.
Why FSH is the value that stands out first
FSH is follicle-stimulating hormone. It comes from the pituitary gland and signals the ovaries to allow an egg to mature.
As feedback from the ovaries declines, the pituitary gland increases the signal. The FSH level therefore rises in response to a change, not as its cause.
For the late phase of the menopausal transition, the MSD Manual gives a specific reference: FSH above 25 IU/L on cycle days 2 to 5 (as of January 2024).
The cycle days in this information are not incidental
The information contains two details. The number above 25 IU/L is one, and cycle days 2 to 5 are the other; both belong together.
An FSH level measured on a different day of the cycle cannot meaningfully be compared with this figure. The same applies if the cycle has already become irregular and the day is harder to determine.
What this means for planning a test is covered in the companion article Hormone levels and the right day of the cycle. This article here focuses on the order of the values.
The stages compared
The MSD Manual divides the process into stages. The table compares three of them using the same four criteria (as of January 2024).
| Criterion | Early transition | Late transition | Late postmenopause |
|---|---|---|---|
| Cycle | Variable length: a persistent difference of at least 7 days between consecutive cycles | Amenorrhea for at least 60 days | No more menstrual bleeding |
| FSH | Elevated but variable | High on cycle days 2 to 5, above 25 IU/L | Stabilizes at a high level |
| What a measurement can accomplish | Little, because the value fluctuates: a single data point can be misleading in either direction | More informative when the cycle day is correct and the value is measured repeatedly | A confirmation of what the overall course already shows |
| What is useful instead | The recorded cycle calendar over several months | Cycle calendar and repeated measurements together | The symptoms and how to interpret them during the consultation |
The penultimate line is the most practically important. Precisely in the early phase, when most women first consider having a measurement taken, a single value is least informative.
Why this is not an argument against measuring
It may seem logical not to measure at all in the early phase. That conclusion falls short, for two reasons.
The first is the baseline value. A value that does not exist cannot be recovered two years later. Anyone who measures early has a point of comparison for later, and that point exists only if someone establishes it.
The second reason is the other possible explanations. TSH and prolactin are among the obvious considerations when cycles change, and both provide meaningful information regardless of the phase.
What follows from the table is therefore not a rejection, but an expectation. A single FSH value in the early phase does not answer the question of which phase you are in, yet measuring it is still not pointless.
Why a single measurement is rarely enough
The specialist literature draws a remarkably specific conclusion from this.
Elevated but variable: In the early phase, a single FSH value tells you the least.
For evaluating ovarian insufficiency, the MSD Manual, Professional Edition, states that a high FSH level should be remeasured at least twice in one month (as of September 2025).
This requirement is the real answer to the question of what a hormone test can accomplish during perimenopause. It provides one data point, and the meaningful interpretation emerges only from several data points.
For you, this means something very practical. If you have measurements taken, record the date, cycle day, and all medications so that a second measurement can be meaningfully compared later. Without this note, every repeat measurement starts from scratch.
Why hormonal medications change the question
Anyone using a hormonal contraceptive is not measuring their own baseline state. The medication interferes with the same regulatory system whose changes the test is intended to reflect.
The same applies to hormone therapy that has already begun. In both cases, a hormone test describes the situation while using the product, so it only allows limited conclusions about the phase.
In addition, hormonal contraception overrides the cycle itself. This means the observation that this article places first—the cycle length over several months—is missing.
This is not an argument against using the product or against testing. It is a reason to write the product on the same list and not interpret the results on your own.
What should happen between two measurements
The medical literature specifies a monthly interval with at least two repeat tests for evaluating ovarian insufficiency (MSD Manual, Professional Edition, updated September 2025). That is a closely spaced testing schedule.
For the question of where someone is in the menopausal transition, a longer interval is more plausible. A process that typically lasts four to eight years rarely reveals anything new in four weeks.
What remains the same in both cases is the condition. The same cycle day, comparable circumstances, and preferably the same laboratory. Without these three, a second measurement is just a second isolated number.
What other explanations may be involved
Irregular cycles, fatigue, and mood swings are nonspecific. They fit perimenopause and several other conditions at the same time.
The thyroid
In the case of menstrual irregularities, thyroid-stimulating hormone is one of the values usually measured as well to rule out thyroid disease (MSD Manual, Professional Edition, updated September 2025).
This is important because an underactive thyroid is treatable and causes symptoms that overlap with those of perimenopause.
Prolactin
Prolactin also belongs on this list. The same source states that a prolactin level between 50 and 100 ng/ml is considered mildly elevated and is generally attributable to the use of a medication (updated September 2025).
The sister article Prolactin: what affects the level covers what else can influence the result.
Stress and sleep
Sleep deprivation and inadequate recovery rank high among the causes of persistent fatigue (MSD Manual, Professional Edition, updated April 2025). During a phase involving night sweats, this is not a minor detail.
The question of the cause is difficult to separate here. What can be said is this: Anyone who records their sleep duration has a second track to observe alongside their hormone levels.
Who would benefit from testing
Not every cycle change requires a hormone measurement as the next step. The comparison makes that clear in both directions.
Makes sense for you if …
You have already recorded your cycle lengths over several months and want to add numerical data.
You want to establish a baseline value with the date and cycle day recorded, against which a second measurement can be compared.
You do not know your TSH or prolactin levels. Both are obvious things to consider when your cycle changes.
You want to be prepared for a consultation at the doctor’s office rather than having values collected for the first time at your initial appointment.
Probably not if …
You are hoping for a definitive answer to the question of whether menopause has begun. A single value cannot provide that information.
You cannot currently determine the day of your cycle. In that case, there is no reference point against which to interpret FSH.
You have experienced bleeding outside your cycle or after menopause. This should be medically evaluated promptly, regardless of any test result.
You want to base a decision about hormone therapy on it. That decision belongs in a doctor’s office.
What a capillary blood test can show here
A capillary blood self-test does not provide a diagnosis or indicate whether menopause has begun. It provides single time-point values that should be interpreted together with a cycle calendar.
The two tests from mybody®x (MYBODY Lab GmbH) address different questions. The cards explain what they can and cannot do.
Capillary blood test
Menopause Check | Menopause Hormone Test
Measures 8 values: estradiol, FSH, LH, progesterone, SHBG, TSH, testosterone, and DHEA-S. This provides the values discussed in this article, together with the thyroid value as an obvious second question. What the test does not do: It provides single time-point values, not a trend, and the day of the cycle on which the sample is taken is crucial for FSH. It does not say whether menopause has begun, does not provide a diagnosis, and does not replace a medical examination.
Laboratory analysis 3–5 business days after receipt of the sample
Product page information, accessed 13 August 2026
Capillary blood test
Women’s Wellness Check | Women’s Health Test
Measures 18 values, including a complete thyroid profile with TSH, fT3, and fT4, as well as prolactin, SHBG, cortisol, ferritin, vitamin B12, long-term blood sugar, and the cholesterol profile. This covers the explanations discussed alongside perimenopause. What the test does not do: It does not measure FSH, LH, estradiol, or progesterone, and therefore cannot answer the question of which phase of the cycle you are in. It does not provide a diagnosis.
Laboratory analysis 3–5 business days after receipt of the sample
Product page information, accessed 13 August 2026
Four points determine whether a measurement becomes useful information.
Record the cycle
A calendar covering several months provides what a single measurement cannot.
Note the cycle day
The FSH information in the specialist literature refers to cycle days 2 to 5.
Check other explanations
TSH and prolactin are part of the evaluation when cycles change.
Discuss anything unusual
Test results, the cycle calendar, and symptoms belong together in a medical practice.
Chapter at a glance
A capillary blood self-test provides values at a specific point in time and does not tell you whether menopause has begun. Its value lies in establishing a baseline with the date and cycle day and checking the most obvious alternative explanations as well. Four points are decisive: record the cycle, note the cycle day, check other explanations, and discuss anything unusual.
Limitations: what a snapshot cannot tell you
The first limitation is fluctuation. In the early transition phase, FSH is elevated but variable (MSD Manual, professional edition, as of January 2024), and a single point on a fluctuating curve carries little weight.
The second limitation is repetition. A high FSH level should be retested at least twice a month (as of September 2025). A self-test can make this repetition possible, but it does not eliminate the need for it.
The third limitation is the definition. Menopause is the final menstrual period and can only be determined retrospectively. No laboratory value can anticipate that retrospective determination.
The fourth limitation is symptoms. Vasomotor symptoms last an average of 7.4 years (as of January 2024) and do not follow any laboratory value. How someone feels does not appear in any test result.
What matters in perimenopause
If you take away one single action from this article, let it be this: Record the first day of every bleeding episode for six months.
The reason is found in the specialist literature itself. The early transition phase is described as a persistent difference of at least seven days between consecutive cycles, and no blood test provides this observation.
At the beginning was the question of which values change first. The answer is: FSH and LH rise before estrogen levels noticeably decline. More important than this sequence, however, is that the calendar comes before the laboratory.
It may seem surprising that an article about hormone levels ultimately points to a calendar. That is exactly what the evidence shows: The early phase is defined by the menstrual cycle, and the laboratory value later confirms what the pattern indicates.
Anyone who has both approaches a conversation differently. Six months of recorded cycle lengths and a report with the date and cycle day together are worth more than either piece of information alone ever could be.
Frequently asked questions
Which hormone level changes first during perimenopause?
FSH and LH rise before estrogen levels decline significantly. The MSD Manual, professional edition, describes the mechanism: reduced concentrations of inhibin and estrogens from the ovaries, which inhibit the release of LH and FSH, lead to a substantial increase in LH and FSH levels (as of January 2024). In the early phase, however, FSH is elevated and variable at the same time.
At what FSH level is the late transition phase considered to have begun?
For the late menopausal transition, the MSD Manual gives an FSH level of over 25 IU/L on cycle days 2 to 5 (as of January 2024). The cycle days are part of the information. The reference range shown on your own laboratory report remains decisive, because reference ranges can vary from one laboratory to another (IQWiG, as of April 2, 2025).
How long does perimenopause last?
It refers to several years before and one year after the last menstrual period, and its duration varies greatly. The menopausal transition within this period typically lasts four to eight years until the final menstrual period (MSD Manual, as of January 2024). The average age of natural menopause in the United States is 51.
Is a single hormone measurement enough?
Not for an evaluation. To investigate ovarian insufficiency, the MSD Manual states that a high FSH level should be measured again at least twice a month (as of September 2025). As a baseline for later comparison, however, a single measurement is useful provided that the date, cycle day, and medications or preparations are recorded.
Which other values are relevant when the menstrual cycle changes?
The MSD Manual lists thyroid-stimulating hormone, among other tests, to rule out thyroid disease, as well as prolactin; a prolactin level between 50 and 100 ng/ml is considered mildly elevated and is usually caused by a medication (as of September 2025). Both explanations are treatable and should therefore be considered before the rarer ones.
Next step
Calendar first, then the values
If you want to supplement your recorded cycle history with numbers, Menopause Check measures 8 values from capillary blood, including estradiol, FSH, LH, and progesterone. It does not tell you whether menopause has begun and does not replace medical evaluation.
Go to the Menopause Check Go to the Women’s Wellness CheckRead more
You might also be interested in
The main article on the symptoms themselves.
When the sample should be collected to make a value comparable.
Sources
- MSD Manual, Professional Edition: Menopause, Pinkerton JV (as of January 2024) – msdmanuals.com
- MSD Manual, Professional Edition: Amenorrhea (as of September 2025) – msdmanuals.com
- MSD Manual, Professional Edition: Fatigue, Wasserman MR (as of April 2025) – msdmanuals.com
- Institute for Quality and Efficiency in Health Care (IQWiG): Understanding Laboratory Values Correctly, as of 04/02/2025 – gesundheitsinformation.de
The verbatim quotation concerning inhibin, estrogens, and LH and FSH levels; the definitions of perimenopause and the menopausal transition; the figures of four to eight years, 51 years, and 7.4 years; the description of the stages with a difference of at least seven days, amenorrhea lasting at least 60 days, and an FSH value above 25 IU/L on cycle days 2 to 5 are taken from source [1]. The information that an elevated FSH value should be repeated at least twice a month, the mention of TSH to rule out thyroid disease, and the information on slightly elevated prolactin between 50 and 100 ng/ml are taken from [2]. The classification of sleep deprivation as a cause of persistent fatigue is based on [3]. The explanation of the reference range and the note about differences between laboratories are taken from [4]. Information on price, values, sample type, and laboratory comes from the mybody®x product pages, accessed on 08/13/2026; processing times follow the central specifications for blood tests. All sources were accessed and reviewed on 08/13/2026.
mybody®x Editorial & Expert Team
Laboratory diagnostics Blood analysis interpretation Nutritional science Nutrigenetics
This article was created by the mybody®x editorial and expert team. The team combines laboratory diagnostics, nutritional science, and the interpretation of blood analyses. Those involved can be found on the authors page.
Published on 08/13/2026 · Last updated on 08/13/2026
The content is intended for general information and does not replace medical advice, diagnosis, or treatment. Reference ranges depend on the laboratory, method, and age; the information on your report is always authoritative.
Share now:
Homocysteine: what the level means and what it leaves unanswered
Prolactin: what affects the level and what shifts it